17 May 2024 in Journal of Zhejiang University-SCIENCE B
Gastric cancer (GC) is one of the most common gastrointestinal tumors. As a newly discovered type of non-coding RNAs, transfer RNA (tRNA)-derived small RNA
18 July 2024 in Carcinogenesis
Since gastric cancer (GC) shows no apparent signs in its early stages, most patients are diagnosed later with a poor prognosis. We therefore seek more sensitive and specific GC biomarkers. Small RNAs formed from tRNAs represent a novel class of non-coding RNAs that are highly abundant in bodily fluids and essential to biological metabolism. This study explores the potential of i-tRF-AsnGTT in gastric cancer diagnostics. To begin with, we sequenced i-tRF-AsnGTT using high-throughput methods. i-tRF-AsnGTT expression levels in GC were determined using real-time fluorescence polymerase chain reaction. Agarose gel electrophoresis, Sanger sequencing, and repeated freezing and thawing were performed to verify molecular properties. A correlation was found between clinical and pathological parameters and i-tRF-AsnGTT expression levels through the χ2 test, and receiver operating characteristic was used to analyze its diagnostic value in GC. In serum, i-tRF-AsnGTT has a low and stable expression level. It can differentiate between patients with gastric cancer and gastritis and healthy donors with better diagnostic efficacy. In combination with clinicopathological parameters, i-tRF-AsnGTT correlates with tumor differentiation; infiltration depth of tumors; tumor, node, metastasis stage; lymph node metastases; and neural/vascular invasion. Serum i-tRF-AsnGTT expression is low in GC patients. Serum from postoperative patients shows increased i-tRF-AsnGTT expression levels. Potentially, this could be used as a biomarker to help diagnose gastric cancer and monitor its prognosis.
1 February 2025 in Carcinogenesis
Colorectal cancer (CRC) is one of the most serious gastrointestinal tumors. The survival rate of patients with advanced stages is meager, so it is urgent to identify new diagnostic biomarkers with high sensitivity and specificity. tRNA-derived small RNAs (tsRNAs) are an emerging class of small non-coding RNAs that are highly abundant in the blood of cancer patients and are associated with various physiological and pathological processes. Therefore, the clinical value of tsRNAs in diagnosing CRC requires further investigation. In this study, we identified the differential expression profiles of tsRNAs in CRC tissues via Pandora sequencing. We selected 5’-tiRNA-His that were significantly highly expressed in CRC plasma and tissues for further investigation. Interestingly, the expression level of 5′-tiRNA-His was increased dramatically in the plasma of CRC patients and correlated with various clinicopathologic parameters. ROC analysis revealed that 5′-tiRNA-His had good diagnostic value in diagnosing CRC patients, superior to that of CEA, CA199, and CA724, and could significantly differentiate patients with CRC from healthy donors and patients with intestinal polyps. Moreover, 5′-tiRNA-His still had good diagnostic efficacy in the diagnosis of patients with early-stage CRC, and the diagnostic efficacy was further elevated when combined with clinically used tumor markers. In conclusion, our study identified plasma 5′-tiRNA-His as a promising biomarker for diagnosing and screening CRC.
13 July 2025 in Molecular Carcinogenesis
21 August 2026 in Advanced Science
Transfer RNA‐derived small RNAs (tsRNAs) are a novel class of small non‐coding RNAs abundant in the bloodstream of cancer patients and involved in various physiological and pathological processes. However, the regulatory mechanisms and clinical significance of tsRNAs in colorectal cancer (CRC) remain unclear. In this study, PANDORA‐seq was used as an exploratory screen of CRC tissues, paired adjacent tissues, and CRC plasma samples, followed by validation in larger independent cohorts. Quantitative real‐time PCR quantified mt‐5’‐tiRNA‐Tyr levels in tissues, plasma, and cells. Functional assays assessed the role of mt‐5’‐tiRNA‐Tyr in CRC. Mechanistic studies utilized RNA pull‐down, mass spectrometry, RNA immunoprecipitation, western blotting, and Co‐immunoprecipitation. Results revealed that mt‐5’‐tiRNA‐Tyr was significantly upregulated in CRC plasma and tissues. In vitro and in vivo studies demonstrated its oncogenic potential. Mechanistic assays showed that mt‐5’‐tiRNA‐Tyr was enriched with HARS2 in RNA pull‐down/RIP assays and associated with reduced HARS2‐mt‐tRNA‐His association, increased HARS2 K91 succinylation, impaired mitochondrial protein translation, and mitochondrial damage. Moreover, succinate accumulation creates a positive feedback loop that enhances CRC proliferation. This study identifies a novel oncogenic tsRNA and uncovers a mechanism by which mt‐5’‐tiRNA‐Tyr promotes CRC proliferation through HARS2 succinylation, supporting further evaluation of plasma mt‐5’‐tiRNA‐Tyr as a candidate circulating biomarker for CRC.